NICEATM/ ICCVAM
This article was originally published in The Rose Sheet
Executive Summary
Public comment is requested on the development of a five-year plan for the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). In a Nov. 13 Federal Register notice, the National Institute of Environmental & Health Sciences solicits input on the highest priority areas for the development of alternatives to the use of animals in safety testing. The public is asked to consider the R&D and validation activities likely to have the greatest impact on alternative testing within the next five years, as well as appropriate measures for evaluating the progress of the alternative methods initiative. Comments should be submitted through the NICEATM/ICCVAM Web site by Dec. 31, 2006. Comments will also be accepted at the Nov. 30 meeting of the Scientific Advisory Committee on Alternative Toxicological Methods in Research Triangle Park, N.C...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.